

U.S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:	APPLICATION NO.:
OC01626K	10/666,424
APPLICANT:	
Kamil Paruch et al.	
FILING DATE:	GROUP:

1	LS	PAT	[FN]	r doci	IME	NTS
•	J.U.	1 /			- IVI	

9/19/2003

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE II
	AA					[-	
	AB						
	AC						
	AD						•
	AE						
	AF						
	AG						
-	AH						
	Al						
	AJ						
	AK			•			

## FOREIGN PATENT DOCUMENTS

Т			DOCUMENT	DATE	COUNTRY	CLAS	S SUB-	TRANS	LATION
			NUMBER				CLASS	YES	NO
		ΔL	EP 0 778 277	06/11/1997	EPO			Ī-—	
7		AM	WO 02/06286	01/24/2002	PCT				
7	M	AN	WO 88/04298	06/16/1988	PCT			<u> </u>	
	7	AO			·				-
	-	AP			-				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ.	Vesely et al., "Inhibition	of Cyclin-D	Dependent	Kinases by I	Purine Analogues"	, Eur. J. Biochem
	(1994), 224: 771-785.					

AR Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", Journal of Clinical Oncology (September 1998), 16(9): 2986-2999.

Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", Eur. J. Biochem. (1997), 243: 527-536. Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Aptineoplastic Agents: The Importance of Sequence of Administration", Cancer Research (August **1**5, 1997), **57**: 3375-3380.

Shiota et al., "Synthesis and Structure- Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-α]pyrimidine Derivatives", Chem. Pharm. Bull. (1999), 47(7): 928-938.

Xasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Hyrazolo[1,5-q]pyrimidines.", Chem. Pharm. Bull. (1962), 10: 620-626.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or hot citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

01	PEvere
MAR	31 2004 2
2	\$ \\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
ROPAY	PLA: POS

U.S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: **APPLICATION NO.:** OC01626K 10/666,424

	TATENT AND TRADEWARK OFFICE				UCU1626K 10/666,424						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					APPLICANT: Kamil Paruch et al.						
<u> </u>	(U	se several sheets it	necessary	)	FILING DATE: GROUP: 09/19/2003						
			U.S. PATE	ENT DOCU	MENTS				_		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	N	AME	CLASS	SUB- CLASS	FILING APPRO	DATE II		
	AA						T :				
	AB				_						
	AC										
	AD							1			
	AE										
	AF			1							
•	AG										
	AH						1	1			
	Al		T .								
	AJ							1			
	AK				-						
	_	FC	DREIGN PA	ATENT DOC	UMENTS						
		DOCUMENT MUMBER	DATE	COUNTRY		CLASS	SUB- CLASS	TRANS	LATION		
	AL	WO 2002 060492 A	08/08/2002	w	IPO						
	ΑМ										
	AN						1		1		
	AO										
	AP							<b>†</b>	1		
	OTI	HER DOCUMENTS	(Includina	Author Title	e Date Pe	rtinent Pa	iges Et	<u> </u>			
	AQ	· · · · · · · · · · · · · · · · · · ·	<u> </u>		,		<i>3,</i> <b>-</b> .	<del></del>			
	AR										
	AS					· · · · · · · · · · · · · · · · · · ·					
	AT										
	AU		· · · · · · · · · · · · · · · · · · ·					<del></del>			
	AV	· · · · · · · · · · · · · · · · · · ·									
EXAMINER		. //		DATE C	ONSIDERED	) /					
	th	11/		20		1			•		
		VVV 7/	)		リナ	10.6					
EXAMINE	R: In	itial if reference conside	ered, whether	or not citation	is in conform		APEP 60	9: Draw	/ line		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:	APPLICATION NO.:	
OC01626K	10/666,424	
APPLICANT:		
Kamil Paruch et al.		
FILING DATE:	GROUP:	•

				Kamil Paruch et al.					
	(U	se several sheets	if necessal	ry)	FILING DATE: 09/19/2003		GROUP	:	
			U.S. PAT	TENT DOCUM					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NA	ME	CLASS		FILING APPRO	
	AW						1 32 130	1	
	AX							1	
	AY		ļ <u> </u>						
·	AZ								
	BA		<u> </u>			ļ	ļ		
<u> </u>	BB BC			<del></del>		<del> </del>	<u> </u>	<u> </u>	
	BD		<del></del>			<del> </del>		<b>↓</b>	
	BE		<del> </del>	<del> </del>	<del></del>	<b></b>	<del> </del>	<del> </del>	
<del></del>	BF		<del> </del>	<del> </del>	<u> </u>	<del> </del>		<del>                                     </del>	
	BG		<del></del>	<del> </del>	- · · · · · · · · · · · · · · · · · · ·			<del> </del>	
		·	COSTIONS	1 TENT DOG		<u> </u>	L	<u> </u>	<del></del>
	· 			PATENT DOC	UMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUB-		LATION
A	BH	WO 02/10162	00/07/0000			ļ	CLASS	YES	NO
/	BI	WU 02/10162	02/07/2002	. WII	<u> </u>		<del></del>	<del> </del>	<del> </del>
/	BJ		<del> </del>	<del></del>		<del> </del>		<del> </del>	<b>_</b>
	BK	<del> </del>				<del> </del>	<del> </del>	<del>                                      </del>	ļ
	BL		<del></del>			<del> </del>	<del> </del> -	╁╌	<del> </del>
		IED DOO! !\AE\IZ				<del></del>	<u> </u>	<u> </u>	<u> </u>
	BM	HER DOCUMENT	S (Includin	g Author, Title	∍, Date, Perti	inent Pa	iges, Et	c.)	
	BIVI	A. Sanderowicz et al Dependent Kinase Ir 2009 (1998).	nhibitor, in Pat	tients with Refrac	ctory Neoplasm	ns", <i>J. Clir</i>	n. Oncolo	gy, 16: 2	
K	Z(	J. Vesely et al., "Inhi 224: 771-786 (1994)	bition of Cycli	n-Dependent Kir	nases by Purine	Analogu	es", <i>Eur</i> .	J. Bioch	em.,
	<b>8</b> 0	I. Meijer et al., "Bioch the Cyclin-Depender	nemical and C	Cellular Effects of	f Roscovitine, a	Potent a	nd Select	tive Inhit	oitor of
	BP	K. S. Kim et al., "Dise	covery of Ami	inothiazole Inhibi	itors of Cyclin-C	enenden	t Kinase	2. Synth	<u>l·                                    </u>
/ <b>/</b> \	ا ا	X-ray Crystallograph	ic Analysis, a	nd Biological Act	livities". J. Medi	icinal Che	mistry. 4	5: 3905-	3927
		(2002)					····		
	BQ								
5)111111	BR	1							
EXAMINER		WY	M		ONSIDERED /	7	6		
EXAMINE	<b>37 In</b>	itial if réference consi	dered, whether	er or not citation	is in conformar	nce with N	IPEP 609	; Draw	line
through cita	ition i	if not in conformance	and not consi	dered. Include o	conv of this form	n with nev	et commi	inication	to

applicant.